Eyelid

Skin Expert Dr. Cameron Rokhsar Joins Exclusive Haute Beauty Network

Retrieved on: 
Thursday, October 20, 2022
Physician, Chin, Medicine, Self-signed certificate, U.S. News & World Report, Lenox Hill Hospital, ABC News, Mohs surgery, CBS News, Research, Nose, Private practice, Albert Einstein College of Medicine, Haute Living, Today, Eyelid, Mount Sinai Hospital, Education, Fox News, Castle, Harvard University, Television, Associate, News, Beauty, New York University School of Law, NBC News, Acne, Skin cancer, Good Morning America, Fashion, Veterinary medicine, Dermatology, New York (magazine), Fraxel

MANHATTAN, N.Y., Oct. 20, 2022 /PRNewswire-PRWeb/ -- Dr. Cameron K. Rokhsar, M.D., F.A.A.D., F.A.A.C.S., an internationally renowned laser surgeon, is a double Board Certified dermatologist, dermatologic mohs surgeon, and fellowship-trained cosmetic and laser surgeon in private practice in Manhattan and Long Island. He practices cosmetic and general dermatology with a particular focus on laser and other nonsurgical treatments, aesthetic enhancements with fillers, skin cancer, and its treatment through Mohs Micrographic Surgery, minimally invasive liposuction, and the treatment of acne and acne scars. Dr. Rokhsar is an Associate Professor of Dermatology at Mount Sinai Hospital, where he teaches the cosmetic dermatology clinic.

Key Points: 
  • Dr. Cameron Rokhsar joins Haute Beauty Network as a skin expert representing the Manhattan, NY market.
  • Dr. Rokhsar is an Associate Professor of Dermatology at Mount Sinai Hospital, where he teaches the cosmetic dermatology clinic.
  • As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.
  • For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/
    Brooke Klaiman, Haute Beauty by Haute Living, 5612122126, [email protected]

Novo Seeds Portfolio Company NMD Pharma Reports Positive Top-Line Phase I/IIa Data in Myasthenia Gravis

Retrieved on: 
Tuesday, October 11, 2022
MG, Union, Muscle, Communication, Disease, International Clinical Trials Registry Platform, Seed, Growth, Novo Holdings A/S, Novo Nordisk Foundation, Immunoglobulin G, CHDR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, ODD, Aarhus University, Myasthenia gravis, Food, Degenerative disease, Novo Nordisk, Company, Eyelid, Industry, Administration, NMD, Face, Safety, Neuromuscular Disorders, GMG, Phase, FDA, Fine chemical, Dietary supplement, Pharmaceutical industry

Novo Seeds, the company creation arm of Novo Holdings, played an instrumental role in founding and seeding NMD Pharma in 2015, and has since then been a cornerstone investor for the company.

Key Points: 
  • Novo Seeds, the company creation arm of Novo Holdings, played an instrumental role in founding and seeding NMD Pharma in 2015, and has since then been a cornerstone investor for the company.
  • Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.
  • It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets.
  • NMD Pharma A/S, is a private biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders.

Novo Seeds Portfolio Company NMD Pharma Reports Positive Top-Line Phase I/IIa Data in Myasthenia Gravis

Retrieved on: 
Tuesday, October 11, 2022
MG, Union, Muscle, Communication, Disease, International Clinical Trials Registry Platform, Seed, Growth, Novo Holdings A/S, Novo Nordisk Foundation, Immunoglobulin G, CHDR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, ODD, Aarhus University, Myasthenia gravis, Food, Degenerative disease, Novo Nordisk, Company, Eyelid, Industry, Administration, NMD, Face, Safety, Neuromuscular Disorders, GMG, Phase, FDA, Fine chemical, Dietary supplement, Pharmaceutical industry

Novo Seeds, the company creation arm of Novo Holdings, played an instrumental role in founding and seeding NMD Pharma in 2015, and has since then been a cornerstone investor for the company.

Key Points: 
  • Novo Seeds, the company creation arm of Novo Holdings, played an instrumental role in founding and seeding NMD Pharma in 2015, and has since then been a cornerstone investor for the company.
  • Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.
  • It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets.
  • NMD Pharma A/S, is a private biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders.

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Retrieved on: 
Thursday, September 29, 2022
Medical Supplies, Biotechnology, Technology, Health, Optical, Robotics, Health Technology, Medical Devices, Surgery, Audio, Video, Hardware, Adult, ROI, American Academy, Contraindication, Aphakia, ARGOS, Lists of diseases, Patient, Physician, Irritation, Bleeding, Central Time, Glaucoma, Eye, User, SMS, Cornea, Student, Visual acuity, Approximation error, Direction, Glasses, Surgeon, American Academy of Ophthalmology, Virtual reality, NYSE, Risk, ORA, News, Diabetes, Presbyopia, Region, Disorder, Light, AAO, SS, Eyelid, Incidence, Intraocular lens, Fidelis, Astigmatism, Retina, Maintenance, Patient satisfaction, Cataract, Life: A User's Manual, Quality of life, Use, Solution, Family, Red, Vision system, Iris, Swelling, Miyata, Telescopic sight, Medical imaging, Dentistry, Medicine, Alcon, IOL, Ophthalmology

Now, with the availability of Clareon Toric, I am able to offer my patients a glistening-free,* astigmatism-correcting option for them during surgery.

Key Points: 
  • Now, with the availability of Clareon Toric, I am able to offer my patients a glistening-free,* astigmatism-correcting option for them during surgery.
  • These activities will take place at Alcon booth #3926 at the AAO exhibit hall, on Oct. 1-3 from 9:00 a.m.5:00 p.m. Central Time.
  • The family of Clareon intraocular lenses (IOLs) includes the Clareon Aspheric Hydrophobic Acrylic and Clareon Aspheric Toric IOLs, the Clareon PanOptix Trifocal Hydrophobic IOL, Clareon PanOptix Toric, Clareon Vivity Extended Vision Hydrophobic Posterior Chamber IOL and Clareon Vivity Toric IOLs.
  • In addition, the Clareon Toric IOLs are indicated to correct pre-existing corneal astigmatism at the time of cataract surgery.

NMD Pharma receives Orphan Drug Designation from FDA for NMD670 for the Treatment of Myasthenia Gravis

Retrieved on: 
Tuesday, September 27, 2022
Eyelid, Muscle, MG, Company, Immunoglobulin G, NMD, Myasthenia gravis, Patient, GMG, Novo Holdings A/S, Aarhus University, Research, Union, Communication, Neuromuscular Disorders, Disease, Pharmaceutical industry

NMD Pharma A/S, is a private biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders.

Key Points: 
  • NMD Pharma A/S, is a private biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders.
  • NMD Pharma received initial seed financing in 2016 and have since raised ~80 million from investors including Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, and Jeito Capital.
  • NMD Pharma has demonstrated that ClC-1 inhibition enhances neuromuscular transmission and restores skeletal muscle function, and this novel treatment approach has demonstrated compelling preclinical efficacy data in animal models of myasthenia gravis (MG) and a range of other neuromuscular disorders.
  • There are approximately 100,000 people in the European Union, 65,000 people in the United States and 20,000 people in Japan living with the disease.

Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories

Retrieved on: 
Tuesday, September 13, 2022
Neuroscience, Rash, Headache, Dizziness, YouTube, Health, Toxin (comics), Allergy, Time, Eyelid, Injection, Muscle, Twitter, NYSE, Risk, Elective surgery, FDA, Food, Lambert–Eaton myasthenic syndrome, Research, Virology, Eyebrow, Breast milk, LinkedIn, Senior, Weakness, Face, Life, ABBV, Myasthenia gravis, Protein Data Bank (file format), Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Gastroenterology, EOY, Instagram, Pain, Medication, Severe cognitive impairment, Wheeze, Plastic, Human, Skin infection, Neck pain, ALS, Vitamin, Ageing, Motivation, AbbVie, Catherine Disher, Asthma, Skin care, Education, Fatigue, Xerostomia, Pharmaceutical industry, Entertainment, Birth control, Canning, Vaccine, Cosmetics, Industrial design, Facebook, Allergan, Botulinum toxin

IRVINE, Calif., Sept. 13, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX® Cosmetic 'See Yourself' campaign. After receiving nearly 20,000 submissions to its first-ever open casting call, BOTOX® Cosmetic, the #1 selling product of its kind1, is creating a content series that captures inspiring and intimate accounts of people speaking candidly about how they see themselves and their motivation for being treated with BOTOX® Cosmetic.

Key Points: 
  • At a time when people want transparency and honesty, we are giving them just that, real patients with real results."
  • "The reality is my patients don't want to see more models staring into the camera while striking a posh pose.
  • I choose BOTOX Cosmetic because I believe in the product, the level of scientific rigor behind it and the results it delivers.
  • This campaign gives me yet another reason to continue to choose BOTOX Cosmetic for myself and my patients."

Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis®

Retrieved on: 
Tuesday, September 13, 2022
Adult, Industry, Patient, Clinical trial, U.S. Securities and Exchange Commission, Phase transition, Nasdaq, Eye, RCT, Risk, Time, COVID-19, OSDI, Entrepreneurship, Securities Act of 1933, Conditional sentence, Company, Growth, Intellectual property, Heat, FDA, Duane syndrome, Health, Tax Cuts and Jobs Act of 2017, Forward-looking statement, MIGS, ECP, CEO, Regulation, Severe cognitive impairment, Jumpstart Our Business Startups Act, GLOBE, Intraocular pressure, MGD, Securities Exchange Act of 1934, Eyelid, JOBS, Private Securities Litigation Reform Act, Exocrine gland, Wills Eye Hospital, Randomized controlled trial, Pharmaceutical industry, Medical device, Ciclosporin

Results from the 310-patient, 1:1 randomized SAHARA trial are expected to be available in late Q2 2023.

Key Points: 
  • Results from the 310-patient, 1:1 randomized SAHARA trial are expected to be available in late Q2 2023.
  • SAHARA is the first multicenter, randomized controlled trial designed to evaluate whether treatment with a dry eye therapeutic device (TearCare) demonstrates superiority when randomized against a standard of care dry eye prescription topical medication (Restasis).
  • Patients in the Restasis control group self-administered 1 drop of Restasis twice a day every day for 6 months with clinical assessments completed at the 6-month timepoint.
  • Following the 6-month read-out, all Restasis patients will be crossed over to the TearCare group and receive a TearCare procedure.

Congratulations to our SightMD 2022 Castle Connolly Top Doctors

Retrieved on: 
Friday, September 9, 2022
Cataract, Patient, Premature, Pediatric ophthalmology, Private practice, Audiology, Severe cognitive impairment, Trust, Cornea, NYU, Doctor of Philosophy, Retina, New York Eye and Ear Infirmary, Lotte Strauss, Medicine, Board, Physician, Department, Diagnosis, Science, Education, Glaucoma, Faculty, Lists of scientists, Empathy, MD, Surgeon, FDA, Hatsi, Nassau University Medical Center, Face, Eyelid, Transplant, Eye, Optic nerve, Health, Neuro-ophthalmology, Medical device, Veterinary medicine, Health insurance, Dentistry, Pharmaceutical industry, Ophthalmology, LASIK, PRK

HAUPPAUGE, N.Y., Sept. 9, 2022 /PRNewswire-PRWeb/ -- Castle Connolly announced its "2022 Top Doctors," a list that represents the top seven percent of doctors in the nation. SightMD is proud to announce that 19 of their physicians are among these standouts. SightMD's "Top Doctors" are: Dr. Alexander Hatsis, Dr. Allen Greenbaum, Dr. David Immanuel, Dr. Faye Knoll, Dr. Irene Magramm, Dr. James Gordon, Dr. Jeffrey Martin, Dr. John Mauro, Dr. Laurence Rubin, Dr. Lawrence Buono, Dr. Lawrence Zweibel, Dr. Michelle Liebert, Dr. Norman Saffra, Dr. Paul Choinski, Dr. Paul Sforza, Dr. Richard Nattis, Dr. Seth Potash, Dr. Ted Karl and Dr. William Kasper.

Key Points: 
  • HAUPPAUGE, N.Y., Sept. 9, 2022 /PRNewswire-PRWeb/ -- Castle Connolly announced its "2022 Top Doctors," a list that represents the top seven percent of doctors in the nation.
  • These outstanding doctors were nominated by their peers and thoroughly validated by Castle Connolly's research team to ensure that they deliver the highest quality patient care.
  • SightMD prides itself on having more Castle Connolly "Top Doctors" than any other practice in New York, and are thrilled to announce this year's list and recognize all of our hard working physicians.
  • With over 25 years' experience in researching, reviewing and selecting "Top Doctors," Castle Connolly is a trusted and credible source.

New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Friday, September 9, 2022
PDE4, NDA, Safety, IGA, Form 10-K, Dermatitis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Study, Time, Doctor of Philosophy, Seborrhoeic dermatitis, Nose, U.S. Securities and Exchange Commission, Risk, Itch, Academy, P92, FAAD, Week, Food, LinkedIn, SEC, Psoriasis, Human, GLOBE, Scalp reduction, Nasdaq, Company, FDA, Atopic dermatitis, Journal of the European Academy of Dermatology and Venereology, Twitter, Face, Congress, Scalp, Eyelid, Eyebrow, Patient, Pharmaceutical industry, Cosmetics, Venereology, Facebook, Dermatology

Roflumilast foam demonstrated strong efficacy across multiple endpoints, including 50% of individuals with seborrheic dermatitis achieving IGA clear at week 8.

Key Points: 
  • Roflumilast foam demonstrated strong efficacy across multiple endpoints, including 50% of individuals with seborrheic dermatitis achieving IGA clear at week 8.
  • Roflumilast foam also demonstrated statistically significant improvements compared to vehicle on all secondary endpoints in the trial, including itch, scaling, and erythema (redness).
  • (63.6% with roflumilast foam vs 42.3% vehicle (P=0.0002))
    More than 50% of individuals treated with roflumilast foam achieved an erythema score of 0 at week 8.
  • Roflumilast foam is a once-daily topical foam formulation of roflumilast which the Company is developing for both seborrheic dermatitis and scalp and body psoriasis.

SightMD Physicians named 2022 Super Doctors® and Rising Stars

Retrieved on: 
Thursday, September 1, 2022
Forehead, Orbit, Premature, Pediatric ophthalmology, Audiology, Rockville Centre, New York, Ophthalmology, Retina, Cornea, Cataract, Glaucoma, Physician, Board of directors, Hauppauge, MD, Surgeon, Uveitis, DO, Eyelid, Health, Rising Star, Patient, Neuro-ophthalmology, Pharmaceutical industry, Medical device, Dentistry, Veterinary medicine, Hospital, LASIK

HAUPPAUGE, N.Y., Sept. 1, 2022  /PRNewswire-PRWeb/ -- SightMD is excited to announce the growing list of providers that have been named on the 2022 "Super Doctor" and "Super Doctors Rising Stars" lists. Dr. Samuel Baharestani, Dr. Michelle Liebert, and Dr. Jeff Martin were recognized as among the best in their field by the "2022 New York Super Doctors" report. The number of doctors who receive this honor is limited to approximately five percent of the region's active physicians. Additionally, Dr. Brad Kligman, Dr. Amy Mehta, Dr. Alanna Nattis, Dr. Eric Rosenberg, Dr. Shetal Shah, Dr Gaurav Chandra, Dr. Leon Rafailov, and Dr. Sabah Shah were recognized as "Super Doctors Rising Stars" for having demonstrated noteworthy achievements early in their careers. The number of doctors who receive this honor is limited to approximately 2.5 percent of the region's active physicians.

Key Points: 
  • SightMD is excited to announce the growing list of providers that have been named on the 2022 "Super Doctor" and "Super Doctors Rising Stars" lists.
  • HAUPPAUGE, N.Y., Sept. 1, 2022 /PRNewswire-PRWeb/ -- SightMD is excited to announce the growing list of providers that have been named on the 2022 "Super Doctor" and "Super Doctors Rising Stars" lists.
  • Dr. Samuel Baharestani, Dr. Michelle Liebert, and Dr. Jeff Martin were recognized as among the best in their field by the "2022 New York Super Doctors" report.
  • The number of doctors who receive this honor is limited to approximately 2.5 percent of the region's active physicians.